<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887054</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00045495</org_study_id>
    <nct_id>NCT01887054</nct_id>
  </id_info>
  <brief_title>Freezing of Gait in Parkinson's Disease</brief_title>
  <acronym>FOG</acronym>
  <official_title>Effect of Visuospatial Training Tasks on Freezing of Gait in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate whether a specific visuospatial training task will change&#xD;
      gait performance of Parkinson's disease (PD) patients in doorways, specifically freezing of&#xD;
      gait.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, prospective, single-blinded six-week study in PD patients with&#xD;
      freezing of gait (FOG).&#xD;
&#xD;
      This study will involve 2 study groups:&#xD;
&#xD;
      Group A - training group; Group B - no training group/controls.&#xD;
&#xD;
      Both groups will complete a gait evaluation and neuropsychological testing. Group A will also&#xD;
      practice an in-home visuospatial task for 30 minutes, 4-6 days per week for six weeks. Group&#xD;
      B will not complete the in-home tasks.&#xD;
&#xD;
      Participation in this study is expected to last 6-8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Double Limb Support (DLS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Primary outcome will be the percent of the gait cycle spent in DLS. This will be evaluated using a GaitRite via a continuous walk, with subjects walking an 18-20 meter oval loop three times continuously.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Training Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There are 2 study visits. Subjects in this group will complete the following:&#xD;
Visit 1&#xD;
Gait evaluation&#xD;
Neuropsychological testing&#xD;
Questionnaires and assessments&#xD;
Taught how to complete a visual problem-solving task (Tower of Hanoi)&#xD;
Given a diary to record training at home.&#xD;
In-home&#xD;
â€¢For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1&#xD;
Visit 2&#xD;
Gait evaluation&#xD;
Neuropsychological testing&#xD;
Questionnaires and assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Training Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>There are 2 study visits. Subjects in this group will complete the following:&#xD;
Visit 1&#xD;
Gait evaluation&#xD;
Neuropsychological testing&#xD;
Questionnaires and assessments&#xD;
Visit 2&#xD;
Gait evaluation&#xD;
Neuropsychological testing&#xD;
Questionnaires and assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tower of Hanoi</intervention_name>
    <arm_group_label>Training Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo group - non use of Tower of Hanoi</intervention_name>
    <arm_group_label>Non Training Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: greater than 18 years old and without an upper age limit&#xD;
&#xD;
          -  diagnosis of idiopathic PD exhibiting at least 2 or 3 cardinal signs (bradykinesia,&#xD;
             rigidity, and resting tremor)&#xD;
&#xD;
          -  Ambulate independently without an assistive device for at least 60 meters&#xD;
&#xD;
          -  Freezing of gait episodes confirmed through the FOG-Q and evaluation by a fellowship&#xD;
             trained Movement Disorder neurologist&#xD;
&#xD;
          -  Willingness and ability to participate in training and complete training diary&#xD;
&#xD;
          -  Documented FOG-Q and Unified Parkinson's Disease Rating Scale (UPDRS) II&#xD;
&#xD;
          -  Ability to sign informed consent&#xD;
&#xD;
          -  Pregnant females will be included in the study and there are no known risks to the&#xD;
             pregnant female or fetus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to complete questionnaires&#xD;
&#xD;
          -  Unwillingness to participate in training, complete all questionnaires and training&#xD;
             diary&#xD;
&#xD;
          -  Subjects with secondary causes of parkinsonism&#xD;
&#xD;
          -  Significant dementia (MOCA &lt;20)&#xD;
&#xD;
          -  Prior deep brain stimulation (DBS) surgery or pallidotomy&#xD;
&#xD;
          -  Subjects cannot participate in any form of Physical Therapy, Occupational Therapy or&#xD;
             Speech Therapy during the study period&#xD;
&#xD;
          -  Subjects cannot start any new medications during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Stacy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2013</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

